Results 41 to 50 of about 13,925,210 (307)

Line of Second Wall [PDF]

Palestine Exploration Quarterly, 1888
n ...
openaire   +1 more source

Biphasic Clinical Course of Pediatric Cytomegalovirus‐Associated Immune Thrombocytopenia: Early Poor Treatment Response but Favorable Long‐Term Outcomes

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Background Cytomegalovirus (CMV) is a recognized trigger of immune thrombocytopenia (ITP); however, its incidence and impact on disease course in children remain controversial. Therefore, we aimed to characterize the clinical course of pediatric patients with CMV‐associated ITP.
Oded Gilad, Ohad Atia, Osama Tanous, Dafna Brik Simon, Michal Dvori, Miriam Cohen, Tracie A. Goldberg, Efraim Bilavsky, Joanne Yacobovich, Orna Steinberg‐Shemer   +9 more
wiley   +1 more source

Treatment failure and mortality factors in patients receiving second-line HIV therapy in resource-limited countries. [PDF]

, 2010
To view this article, click on "Additional Links".CONTEXT: Long-term antiretroviral therapy (ART) use in resource-limited countries leads to increasing numbers of patients with HIV taking second-line therapy. Limited access to further therapeutic options
Mar Pujades-Rodríguez, Pujades-Rodríguez, Mar, Calmy, Alexandra, Brinkhof, Martin A W, Balkan, Suna, Arnould, Line, Brinkhof, Martin A. W.   +6 more
core   +1 more source

“We Cannot Talk as a Family”: Complexities of Survivorship Communication Among Hispanic/Latino Young Adult Survivors of Childhood Cancer, Parents, and Clinicians

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Background Young adult childhood cancer survivors (YA‐CCS) have an increased risk of treatment‐related health complications throughout their lives. Lifelong survivorship care is recommended, yet many YA‐CCS experience disruptions in care during pediatric‐to‐adult transitions and do not receive recommended survivorship care.
Kevin Shanchen Pu, Nicole Fernández‐Viña, Briana C. Martin‐Villa, Daniela Ramirez, Rebecca M. Lewinsohn, Mary Smith, Heidi Boynton, Lidia Schapira, Stephanie M. Smith   +8 more
wiley   +1 more source

Time to switch from first-line to second-line treatment.

, 2018
Time to switch from first-line to second-line treatment.
Qiang Shi (191722), Chien-Hsun Lee (3753640), Ko-Jen Li (730660), Carol L. Gaich (5071301), Wesley Furnback (5071307), Tamas Treuer (5071304), Bruce C. M. Wang (5071313), Wen-Shuo Wu (5071310), Chao-Hsiun Tang (4242457)   +8 more
core   +1 more source

Classical Complement Pathway Inhibition in a Pediatric Patient With Refractory Immune Thrombocytopenia

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Pediatric refractory immune thrombocytopenia (rITP) is generally characterized by persistent thrombocytopenia and failure to achieve a sustained response to multiple standard therapies. We report a 4‐year‐old female with congenital tufting enteropathy, post‐intestinal transplant patient on immunosuppressants, who developed severe rITP ...
Sarah Hsieh, Susmita Sarangi, Caileigh Pudela, Catherine M. Broome, Tara K. Suntum   +4 more
wiley   +1 more source

Corrigendum

Drug Design, Development and Therapy, 2011
Paller CJ, Antonarakis ES. Cabazitaxel: a novel second-line treatment for metastatic castration-resistant prostate cancer.Drug Design, Development and Therapy. 2011;5:117–124.
Channing J Paller, Emmanuel S Antonarakis   +1 more
doaj  

Standardization of first and second-line antitubercular susceptibility testing using BacT Alert 3D system: a report from a tertiary care centre in India

Brazilian Journal of Infectious Diseases
Resurgence of multidrug resistant tuberculosis has lead to demand for rapid susceptibility testing. Conventional methods take > 3 weeks and are tedious. Automated methods have superseded them for first line drug susceptibility testing.
Deepthi Nair, Malini R. Capoor, Deepti Rawat, Lakshmi Srivastava, Pushpa Aggarwal   +4 more
doaj   +1 more source

Second-Line Chemotherapy for Intrahepatic Cholangiocarcinomas: What Is the Real Gain?

Life, 2023
Background: The presence of actionable alterations in advanced biliary tract cancer patients opened new therapeutic possibilities for second-line treatments. However, for around 60% of the patients, chemotherapy remains the only therapeutic option.
Ingrid Garajová, Fabio Gelsomino, Massimiliano Salati, Anna Mingozzi, Marianna Peroni, Stefania De Lorenzo, Alessandro Granito, Francesco Tovoli, Francesco Leonardi   +8 more
doaj   +1 more source

Combinations of second-line treatment.

, 2019
Combinations of second-line treatment.
Magdalena Piróg (6281519), Lubomir Bodnar (6281510), Dorota Babczyk (6281516), Tomasz Basta (6281501), Robert Jach (6281531), Anna Horbaczewska (6281528), Paweł Knapp (6281504), Iwona Gawron (6281513), Paweł Blecharz (6281507), Anna Markowska (6281525), Tomasz Kluz (6281522)   +10 more
core   +1 more source